Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.03)
# 512
Out of 5,067 analysts
76
Total ratings
55.71%
Success rate
10.72%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $28.04 | +24.82% | 3 | Nov 19, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $587.92 | +8.86% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $106.24 | -12.46% | 12 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $76 → $88 | $87.69 | +0.35% | 3 | Oct 28, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $41.79 | +5.29% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $10.57 | +41.91% | 1 | Oct 15, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | $50 | $31.24 | +60.05% | 1 | Oct 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $53 → $68 | $65.59 | +3.67% | 4 | Sep 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $761.45 | +6.64% | 8 | Aug 11, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $11.77 | -6.54% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $199 | $176.82 | +12.54% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $17.01 | +46.97% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,070.16 | -3.01% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $229.51 | -5.45% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $25.22 | +26.88% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $23.48 | +112.95% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.01 | +5,246.53% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $9.84 | +52.44% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $17.15 | +109.91% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $67.21 | +4.15% | 4 | May 29, 2024 |
Terns Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $28.04
Upside: +24.82%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $587.92
Upside: +8.86%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $106.24
Upside: -12.46%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $76 → $88
Current: $87.69
Upside: +0.35%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $41.79
Upside: +5.29%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $10.57
Upside: +41.91%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $31.24
Upside: +60.05%
Kymera Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $53 → $68
Current: $65.59
Upside: +3.67%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $761.45
Upside: +6.64%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $11.77
Upside: -6.54%
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $176.82
Upside: +12.54%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $17.01
Upside: +46.97%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,070.16
Upside: -3.01%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $229.51
Upside: -5.45%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.22
Upside: +26.88%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $23.48
Upside: +112.95%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.01
Upside: +5,246.53%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $9.84
Upside: +52.44%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $17.15
Upside: +109.91%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $67.21
Upside: +4.15%